$32.3M Boost: City of Hope’s Groundbreaking Therapies

City Of Hope

City of Hope, a prominent cancer research and treatment organization in the United States, has received a grant of $32.3 million from the California Institute for Regenerative Medicine (CIRM). Funding Allocation The funds will be used to support three novel Phase 1 clinical trials that focus on innovative cell and gene therapy treatments for patients […]

Revolution in Cancer Treatment: LIfT’s iPSCs Breakthrough

Lift Biosciences logo

LIfT BioSciences, a rapidly emerging biotech company, has announced a significant breakthrough in cancer cell therapies. The company has successfully demonstrated proof-of-concept production of its patented cancer-killing alpha neutrophils from induced pluripotent stem cells (iPSCs). This development marks a new era of affordable and effective cancer cell therapies. The company’s second-generation platform, iN-LIfT, derived from […]

One Niche to Rule Them All: Stem Cell-Lymphatic Interactome in Regeneration and Cancer

stem cell lymphatic interactome in regeneration and cancer

Shiri Gur-Cohen, Ph.D., UC San Diego, explains how her lab studies how epithelial stem cells communicate with their vascular microenvironment to advance regeneration and combat metastatic diseases. Video Transcript: [MUSIC] I’m excited to share with you today the work that we’re doing in my laboratory to enhance regeneration and to fight cancer. In my laboratory, […]

Updated Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy

Invectys logo

HOUSTON, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) — Invectys, Inc. and CTMC, a joint venture between MD Anderson Cancer Center and National Resilience, Inc., today announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for a Phase 1/2a clinical study of IVS-3001, Invectys’s lead engineered human leukocyte antigen A (HLA-G) targeting chimeric antigen […]

Angiocrine Bioscience Announces it has been awarded a $15M Grant from the California Institute for Regenerative Medicine for AB-205 Phase 3 Clinical Trial

Angiocrine Bioscience logo

SAN DIEGO, Dec. 19, 2022 /PRNewswire/ — Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company today announced that the California Institute for Regeneration Medicine (CIRM) has approved investing $15M in the Phase 3 registration study AB-205-301 (E-CELERATE), a multi-center, randomized, double-blind, placebo-controlled study of AB-205 in adults with lymphoma undergoing high-dose chemotherapy (HDT) and autologous hematopoietic cell transplantation (AHCT). AB-205 […]

Grant Awarded to Develop Genetically Engineered Stem Cell Products to Fight Gastroesophageal Cancer

Dr Saar Gill

NEW YORK, Nov. 9, 2022 /PRNewswire/ — The DeGregorio Family Foundation with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative (GEMINI) has awarded $250,000 to Saar Gill, MD, PhD, of the University of Pennsylvania, to improve immunotherapy in gastroesophageal cancer by using the tools of genetic engineering to modify human blood-forming stem cells to produce highly specialized cancer-eating cells called […]

CAR T-Cell Therapy: Ask Dr. Alaa Ali

CAR T-Cells

Alaa Ali, MD, MSC, is a clinician, instructor, and investigator in clinical and translational research at MedStar Georgetown’s Stem Cell Transplant and Cellular Immunotherapy program. In the following video, Dr. Alaa Ali explains what CAR T-cell therapy is and how it works, what the process is for creating CAR T-cells to fight cancer, the success […]

The Journey of a Cancer-Fighting Stem Cell Therapy

Dr Ravi Majeti - journey of a cancer-fighting stem cell therapy

Frontiers in Medicine 2022 gathered Stanford Medicine’s scientific and philanthropic communities in the historic Frost Amphitheater to explore a future of medicine that is both innovative and human-centered. A future that harnesses AI and big data to transform how we deliver care. A future where knowledge of human biology at a cellular, molecular, and genomic […]